Literature DB >> 19862823

Distinct MHC gene expression patterns during progression of melanoma.

Yan Degenhardt1, Jia Huang, Joel Greshock, Galene Horiates, Katherine Nathanson, Xiaolu Yang, Meenhard Herlyn, Barbara Weber.   

Abstract

Abnormal expression of major histocompatibility complex (MHC) molecules in melanoma has been reported previously. However, the MHC molecule expression patterns in different growth phases of melanoma and the underlying mechanisms are not well understood. Here, we demonstrate that in vertical growth phase (VGP) melanomas, MHC genes are subject to increased rates of DNA copy number gains, accompanied by increased expression, in comparison to normal melanocytes. In contrast, MHC expression in metastatic melanomas drastically decreased compared to VGP melanomas, despite still prevalent DNA copy number gains. Subsequent investigations found that the master transactivator of MHC genes, CIITA, was also significantly downregulated in metastatic melanomas when compared to VGP melanomas. This could be one of the mechanisms accounting for the discrepancy between DNA copy number and expression level in metastatic melanomas, a potentially separate mechanism of gene regulation. These results infer a dynamic role of MHC function in melanoma progression. We propose potential mechanisms for the overexpression of MHC molecules in earlier stages of melanoma as well as for its downregulation in metastatic melanomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19862823      PMCID: PMC2796267          DOI: 10.1002/gcc.20728

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  47 in total

Review 1.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.

Authors:  F M Marincola; E M Jaffee; D J Hicklin; S Ferrone
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

Review 2.  A listing of human tumor antigens recognized by T cells.

Authors:  N Renkvist; C Castelli; P F Robbins; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  2001-03       Impact factor: 6.968

3.  Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines.

Authors:  B L Goodwin; H Xi; R Tejiram; D D Eason; N Ghosh; K L Wright; U Nagarajan; J M Boss; G Blanck
Journal:  Cell Growth Differ       Date:  2001-06

4.  Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene.

Authors:  David Mu; Liyun Chen; Xiping Zhang; Lei-Hoon See; Christina M Koch; Clifford Yen; James Jiayuan Tong; Lori Spiegel; Ken C Q Nguyen; Allyson Servoss; Yue Peng; Lin Pei; Jeffrey R Marks; Scott Lowe; Timothy Hoey; Lily Yeh Jan; W Richard McCombie; Michael H Wigler; Scott Powers
Journal:  Cancer Cell       Date:  2003-03       Impact factor: 31.743

5.  Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter.

Authors:  V Deffrennes; J Vedrenne; M C Stolzenberg; J Piskurich; G Barbieri; J P Ting; D Charron; C Alcaïde-Loridan
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

6.  Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization.

Authors:  M Balázs; Z Adám; A Treszl; J Hunyadi; R Adány
Journal:  Cytometry       Date:  2001-08-15

7.  Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.

Authors:  Kapaettu Satyamoorthy; Gang Li; Michelle R Gerrero; Marcia S Brose; Patricia Volpe; Barbara L Weber; Patricia Van Belle; David E Elder; Meenhard Herlyn
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

8.  Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.

Authors:  Roberta Mortarini; Adriano Piris; Andrea Maurichi; Alessandra Molla; Ilaria Bersani; Aldo Bono; Cesare Bartoli; Mario Santinami; Claudia Lombardo; Fernando Ravagnani; Natale Cascinelli; Giorgio Parmiani; Andrea Anichini
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

9.  MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.

Authors:  Tomohide Tatsumi; Lisa S Kierstead; Elena Ranieri; Loreto Gesualdo; Francesco P Schena; James H Finke; Ronald M Bukowski; Vladimir Brusic; John Sidney; Alessandro Sette; Theodore F Logan; Yvette L Kasamon; Craig L Slingluff; John M Kirkwood; Walter J Storkus
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

10.  Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer.

Authors:  L A Koopman; W E Corver; A R van der Slik; M J Giphart; G J Fleuren
Journal:  J Exp Med       Date:  2000-03-20       Impact factor: 14.307

View more
  13 in total

1.  Construction and phenotypic analysis of mice carrying a duplication of the major histocompatibility class I (MHC-I) locus.

Authors:  Olga Ermakova; Ekaterina Salimova; Lukasz Piszczek; Cornelius Gross
Journal:  Mamm Genome       Date:  2012-07-07       Impact factor: 2.957

2.  Atypical amplification of chromosome region 22q12 in melanoma: A case report.

Authors:  Giuseppina Liguori; Monica Cantile; Francesca Collina; Laura Marra; Anna DE Chiara; Renato Franco; Michele Caraglia; Gerardo Botti; Mirella D'Andrea; Giovanni Francesco Nicoletti
Journal:  Oncol Lett       Date:  2015-04-27       Impact factor: 2.967

3.  The Transcriptional Landscape of BRAF Wild Type Metastatic Melanoma: A Pilot Study.

Authors:  Elena Lastraioli; Federico Alessandro Ruffinatti; Giacomo Bagni; Luca Visentin; Francesco di Costanzo; Luca Munaron; Annarosa Arcangeli
Journal:  Int J Mol Sci       Date:  2022-06-21       Impact factor: 6.208

4.  From melanocyte to metastatic malignant melanoma.

Authors:  Bizhan Bandarchi; Linglei Ma; Roya Navab; Arun Seth; Golnar Rasty
Journal:  Dermatol Res Pract       Date:  2010-08-11

5.  Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen.

Authors:  Elena Shklovskaya; Alexandra M Terry; Thomas V Guy; Adrian Buckley; Holly A Bolton; Erhua Zhu; Jeff Holst; Barbara Fazekas de St. Groth
Journal:  Immunol Cell Biol       Date:  2016-02-03       Impact factor: 5.126

6.  Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood.

Authors:  Jocelyn Charlton; Richard D Williams; Mark Weeks; Neil J Sebire; Sergey Popov; Gordan Vujanic; William Mifsud; Marisa Alcaide-German; Lee M Butcher; Stephan Beck; Kathy Pritchard-Jones
Journal:  Genome Biol       Date:  2014-08-19       Impact factor: 13.583

7.  Metastatic melanoma cells evade immune detection by silencing STAT1.

Authors:  JoDi Lynn Osborn; Susanna F Greer
Journal:  Int J Mol Sci       Date:  2015-02-17       Impact factor: 5.923

Review 8.  Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.

Authors:  Anna E Kersh; Maiko Sasaki; Lee A Cooper; Haydn T Kissick; Brian P Pollack
Journal:  Front Pharmacol       Date:  2016-09-26       Impact factor: 5.810

Review 9.  CD4 and CD8 T lymphocyte interplay in controlling tumor growth.

Authors:  Dmitrij Ostroumov; Nora Fekete-Drimusz; Michael Saborowski; Florian Kühnel; Norman Woller
Journal:  Cell Mol Life Sci       Date:  2017-10-14       Impact factor: 9.261

10.  Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Authors:  Douglas B Johnson; Monica V Estrada; Roberto Salgado; Violeta Sanchez; Deon B Doxie; Susan R Opalenik; Anna E Vilgelm; Emily Feld; Adam S Johnson; Allison R Greenplate; Melinda E Sanders; Christine M Lovly; Dennie T Frederick; Mark C Kelley; Ann Richmond; Jonathan M Irish; Yu Shyr; Ryan J Sullivan; Igor Puzanov; Jeffrey A Sosman; Justin M Balko
Journal:  Nat Commun       Date:  2016-01-29       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.